Distribution date: 15 September 2006

Products Covered: Hair creams (HS: 330590;  ICS: 71.100.70)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Hair creams (HS: 330590;  ICS: 71.100.70)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Bath preparations (HS: 3307;  ICS: 71.100.70)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Bath preparations (HS: 3307;  ICS: 71.100.70)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Carbon Black used in rubber products (HS: 2803;  ICS: 83.040.20)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Carbon Black used in rubber products (HS: 2803;  ICS: 83.040.20)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Carbon Black used in rubber products (HS: 2803;  ICS: 83.040.20)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Products Covered: Carbon Black used in rubber products (HS: 2803;  ICS: 83.040.20)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Health Canada has received a submission to permit the use of the xylanase enzyme from a Bacillus subtilis organism, Bacillus subtilis DIDK 0115 (pUB110 OIS2) genetically modified to contain multiple copies of the gene coding for the xylanase enzyme, in the production of bread, flour, whole wheat flour and unstandardized bakery products at levels consistent with good manufacturing practice. Evaluation of available data supports the safety and effectiveness of this xylanase enzyme derived from Bacillus subtilis DIDK 0115 (pUB110 OIS2). The use of this xylanase enzyme derived from this modified micro-organism will benefit the consumer through the availability of quality food products. It will also benefit industry through more efficient and improved manufacturing conditions. Therefore, it is the intention of Health Canada to recommend that the Food and Drug Regulations be amended to permit the use of this xylanase enzyme derived from the micro-organism specified above in the production of bread, flour, whole wheat flour and unstandardized bakery products at levels consistent with good manufacturing practice. As a means to improve the responsiveness of the regulatory system, an Interim Marketing Authorization (IMA) is being issued to permit the immediate use of the xylanase enzyme, as indicated above, while the regulatory process is undertaken to formally amend the Regulations. A revision to this notification will be published at the start of the amendment process and Members will be given the opportunity at that time to submit comments on this proposed measure.

Products Covered: Xylanase enzyme (ICS: 67.060)

Regulation Type: Regular notification

Distribution date: 15 September 2006

Health Canada has received a submission to permit the use of the xylanase enzyme from a Bacillus subtilis organism, Bacillus subtilis DIDK 0115 (pUB110 OIS2) genetically modified to contain multiple copies of the gene coding for the xylanase enzyme, in the production of bread, flour, whole wheat flour and unstandardized bakery products at levels consistent with good manufacturing practice. Evaluation of available data supports the safety and effectiveness of this xylanase enzyme derived from Bacillus subtilis DIDK 0115 (pUB110 OIS2). The use of this xylanase enzyme derived from this modified micro-organism will benefit the consumer through the availability of quality food products. It will also benefit industry through more efficient and improved manufacturing conditions. Therefore, it is the intention of Health Canada to recommend that the Food and Drug Regulations be amended to permit the use of this xylanase enzyme derived from the micro-organism specified above in the production of bread, flour, whole wheat flour and unstandardized bakery products at levels consistent with good manufacturing practice. As a means to improve the responsiveness of the regulatory system, an Interim Marketing Authorization (IMA) is being issued to permit the immediate use of the xylanase enzyme, as indicated above, while the regulatory process is undertaken to formally amend the Regulations. A revision to this notification will be published at the start of the amendment process and Members will be given the opportunity at that time to submit comments on this proposed measure.

Products Covered: Xylanase enzyme (ICS: 67.060)

Regulation Type: Regular notification